Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBM24 is a single-domain RNA binding protein containing an RNA Recognition Motif (RRM) at its N-terminus, which preferentially binds GU-rich sequences in target mRNAs. It is strongly and dynamically expressed in specific tissues, especially cardiac and skeletal muscle, and developmental sensory structures. RBM24 is essential for proper alternative splicing of muscle and heart genes, such as ACTN2, TTN, MYH6, and MYBPC3, and for cytoplasmic polyadenylation of lens mRNAs. It also regulates mRNA stability, including p21, p63, and SLC7A11, affecting cell cycle progression, apoptosis, and protection against ferroptosis. Mutations or deficiency in RBM24 are linked to congenital muscle, heart, and sensory disorders in animal models, and its downregulation is associated with certain human cancers. Although no direct drugs currently target RBM24, its molecular pathways present potential opportunities for therapeutic intervention.
Modulation of mRNA splicing, stability, and translation; Protection against ferroptosis by stabilizing SLC7A11 mRNA; Interaction with translation initiation factor eIF4E to modulate p53 translation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA binding motif protein 24 (RBM24).